M&A

M&A

DRL acquires injectable portfolio from US-co Eton Pharma for $50-M

BSE Announcement,   Economic Times  

Publicly listed Dr. Reddy's Laboratories (DRL) has acquired a portfolio of branded and generic injectable products from Illinois-based Eton Pharmaceuticals. Dr. Reddy's will pay USD 5 million upfront in cash, plus contingent payments of up to USD 45 million. The acquired portfolio includes the Biorphen (phenylephrine hydrocholoride) injection and Rezipres (ephedrine hydrochloride) injection NDAs (new drug application) with nine separate combinations of strengths and presentations and one first- to-file approved ANDA for Cysteine Hydrochloride for the US. The value of total addressable market for these products in the US is estimated to be around USD 174 million for the calendar year ending April 2022.